

## Special Issue

# Diagnosis of Hematologic Malignancies

### Message from the Guest Editors

An accurate diagnosis is necessary for a correct prognostic stratification and an adequate therapeutic selection. Although morphology continues to represent the indispensable starting point in the diagnostics of hematological neoplasms, new classifications tend to define nosological entities based on the underlying genetic mechanisms of disease. The World Health Organization's (WHO) classification of tumors of hematopoietic and lymphoid tissues has provided a global reference for the diagnosis of hematological neoplasms since its third edition in 2001. This classification is based on integrating morphologic (cytology and histology), immunophenotypic, molecular, and cytogenetic data. Recently, in addition to the 2022 edition of the WHO classification, the International Consensus Classification (ICC) system for hematological neoplasms has been published. While many definitions proposed by the ICC and WHO 2022 are concordant, some differ in a number of key aspects and could impact the design of clinical trials, drug development, and regulatory approval, in addition to, as a consequence, patient care.

### Guest Editors

Dr. Leonor Arenillas

1. Hematological Cytology Laboratory, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain
2. Translational Research on Hematological Neoplasms Group, Cancer Research Program, Hospital del Mar Research Institute (HMRI), 08003 Barcelona, Spain

Dr. Xavier Calvo

1. Hematological Cytology Laboratory, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain
2. Translational Research on Hematological Neoplasms Group, Cancer Research Program, Hospital del Mar Research Institute (HMRI), 08003 Barcelona, Spain

### Deadline for manuscript submissions

closed (15 December 2024)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/151568](https://mdpi.com/si/151568)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)